Standard Operating Procedure for Deficiency Letter Assessment and Response Planning
| Department | Regulatory Affairs |
| SOP No. | RA/2026/725 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 14/04/2026 |
| Effective Date | 14/04/2026 |
| Review Date | 14/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a standardized and systematic approach for the receipt, assessment, and planned response to deficiency letters issued by health authorities. The objective is to ensure timely, accurate, and comprehensive handling of regulatory queries that impact product registration, compliance, and market access, thereby supporting regulatory control and quality assurance within the pharmaceutical environment.
Scope
This SOP applies to all regulatory affairs personnel and associated functional areas involved in the management of deficiency letters from health authorities. It covers the assessment of deficiency letter contents, planning and documenting responses, preparing supporting data, and submitting replies within required timelines. This SOP is applicable to all product types, dosage forms, regulatory submissions, and related documentation. It excludes other forms of regulatory communication such as general enquiries or pharmacovigilance reports unless specifically linked to deficiency letters.
Responsibilities
- Regulatory Affairs Executive: Receive deficiency letters, initiate assessment, and coordinate response preparation.
- Regulatory Affairs Manager: Review assessments and proposed responses for completeness and compliance.
- Quality Assurance Representative: Verify that responses comply with GMP and company policies.
- Subject Matter Experts (e.g., R&D, Manufacturing, Quality Control): Provide technical information and data as required.
- Document Control: Manage document versions and archive final response documentation.
- Regulatory Affairs Head: Oversee the coordination and ensure timelines are met.
Accountability
The Head of Regulatory Affairs is accountable for the implementation, compliance monitoring, periodic review, and effectiveness of this SOP. This role is also responsible for escalation of unresolved issues and ensuring adherence to regulatory timelines and quality standards.
Procedure
1. Receipt and Logging: Upon receipt of a deficiency letter, the Regulatory Affairs Executive shall log the letter into the deficiency management system and notify the Regulatory Affairs Head and relevant stakeholders within one business day.
2. Preliminary Review: Conduct an initial review to identify the nature and scope of the deficiency, affected dossiers or submissions, and deadlines for response submission.
3. Assigning Responsibility: Distribute the letter content to the relevant functional experts for detailed technical evaluation based on the specific queries raised.
4. Data Collection and Analysis: Collate all required data, batch records, validation reports, method details, or other supporting documents relevant to each query. Ensure the data adequacy and accuracy for regulatory submission.
5. Response Drafting: Prepare detailed, clear, and compliant responses addressing each point raised in the deficiency letter. Drafts shall include references to supporting documents and rationale where applicable.
6. Internal Review and Approval: Circulate the draft response among Regulatory Affairs Manager, QA, and concerned departments for review. Incorporate comments and finalize the response document.
7. Quality Checks and Compliance Verification: QA shall perform a final compliance check ensuring that responses meet GMP requirements and regulatory expectations.
8. Document Control and Versioning: Assign document numbers, version controls, and ensure proper archiving of all final responses and corresponding annexures in the document management system.
9. Submission of Response: Submit the approved response to the health authority through the prescribed communication channel within the stipulated timeline. Obtain submission acknowledgment where applicable.
10. Follow-up and Closure: Monitor for receipt confirmation, further clarifications, or closure letters from the authority. Document all correspondence and update tracking systems accordingly.
11. Deviations and Escalations: Any delays, discrepancies, or uncertainties encountered during the process shall be escalated immediately to the Regulatory Affairs Head for corrective action and notification to senior management.
12. Record Retention: Maintain all deficiency letters, responses, related data, and correspondence as per company and regulatory record retention policies.
This procedure is designed to ensure thorough, timely, and compliant handling of regulatory deficiency letters to support continuous regulatory compliance and successful product lifecycle management.
Abbreviations
- GMP: Good Manufacturing Practices
- QA: Quality Assurance
- RA: Regulatory Affairs
- R&D: Research and Development
- QC: Quality Control
- HAC: Health Authority Communication
Documents
The following documents are applicable and must be used throughout the deficiency letter management process:
- Deficiency Letter Receipt and Log Sheet (Annexure-1)
- Deficiency Letter Assessment and Response Plan Template (Annexure-2)
- Final Response Submission Cover Letter (Annexure-3)
References
- ICH Q10 Pharmaceutical Quality System
- WHO Good Regulatory Practices Guidelines
- EU GMP Annex 16 – Certification by a Qualified Person and Batch Release
- FDA Guidance for Industry – Responding to Inspections and Deficiency Letters
- Company Quality Management System Policy
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Deficiency Letter Receipt and Log Sheet
| Deficiency Letter Receipt and Log Sheet | |
| Purpose | To document receipt details and initial logging of deficiency letters from health authorities for traceability and tracking. |
| Field | Entry |
|---|---|
| Date Received | 12/04/2026 |
| Received From | Country Health Authority |
| Letter Reference Number | HA/DEF/2026/0345 |
| Product / Dossier Name | XYZ Tablet 20mg |
| Received By | Regulatory Affairs Executive |
| Logged By | Regulatory Affairs Executive |
| Initial Comments | Deficiency relates to stability data clarification |
Annexure-2: Deficiency Letter Assessment and Response Plan Template
| Deficiency Letter Assessment and Response Plan | |
| Purpose | To provide a structured framework for evaluating deficiency letter content and planning appropriate responses and timelines. |
| Field | Data / Instructions |
|---|---|
| Date of Assessment | 13/04/2026 |
| Assessed By | Regulatory Affairs Executive |
| Deficiency Points | 1. Stability data for XYZ Tablet beyond 24 months requested. 2. Labeling discrepancy in batch release document. |
| Responsible Departments | Quality Control, Manufacturing, Labeling |
| Proposed Response Actions | Gather extended stability data, prepare corrected labeling documents. |
| Target Response Date | 20/04/2026 |
| Comments | Ensure cross-check with QA before submission. |
Annexure-3: Final Response Submission Cover Letter
| Final Response Submission Cover Letter | |
| Purpose | To accompany and summarize the regulatory response sent to the health authority addressing all deficiency points. |
| Field | Details |
|---|---|
| Date | 20/04/2026 |
| To | Regulatory Affairs Division Country Health Authority |
| Reference | Response to Deficiency Letter HA/DEF/2026/0345 |
| Subject | Submission of Responses to Deficiency Points for XYZ Tablet 20mg |
| Content Summary | Enclosed are the assessments and supporting documentation addressing the stability data extension request and corrected labeling documents as per deficiency letter. |
| Submitted By | Regulatory Affairs Department |
| Contact Information | Tel: +00-123-4567890 Email: ra-dept@pharmaexample.com |
| Attachments | Annexure A: Stability Data Reports Annexure B: Updated Labeling Documentation |
| Signature | _______________________ |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 14/04/2026 | 1.0 | Initial issue | New SOP creation |